Silence Therapeutics plc (LON:SLN), a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces a further step in the expansion of its chemical modification patent estate.
Silence announces that the US Patent and Trade Mark Office has issued a notice of allowance for US patent application 15/589971.
Silence has made the relevant payment of grant fees and normal practice is that the granted patent will now be issued by the US Patent and Trade Mark Office. The allowed claims of US patent application 15/589971 provide Silence with further protection for its innovative chemical modification technology in the US. Silence believes these allowed claims are relevant to third party medicines in ongoing clinical trials.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, commented:
In allowing this additional patent application for grant, the US Patent and Trade Mark Office has continued to uphold the validity of our expanding US patent estate. We continue to believe that several third party late‐stage clinical RNAi candidates require licences under our patent portfolio.
